1 ETF I Like Better Than Cathie Wood’s Ark Innovation ETF in 2024
An S&P 500 ETF has comparably good long-term results with much fewer wild swings to go with it.
Researchers identify why cancer immunotherapy can cause colitis
Researchers have identified a mechanism that causes severe gastrointestinal problems with immune-based cancer treatment, also finding a way to deliver immunotherapy’s cancer-killing impact without the unwelcome side effect.
2 “Magnificent Seven” Stocks That Could Outperform the Nasdaq in 2024
These companies are killing it in AI and have massive growth potential in the new year.
Is Daktronics a Buy Right Now?
The scoreboard and marketing display veteran is coming back from the dark. Is there room for greater gains after the stock price tripled in 2023?
Why AngioDynamics Stock Got Destroyed Today
The medical technology company is a perennial underperformer, but its latest quarterly report was worse than expected.
MicroStrategy’s Bold Bitcoin Bet: Risks, Rewards, and Future Outlook
Here’s an investor’s guide to the dreadful risks and enchanting rewards of a Bitcoin-driven strategy. Is this the right crypto stock for you?
Why Expedia Stock Was Up 11.5% in December
Wall Street is more bullish and management was likely buying up shares fast.
Feathers from deceased birds help scientists understand new threat to avian populations
Animal ecologists developed an analytical approach to better understand one of the latest threats to feathered creatures: the rise of wind and solar energy facilities.